Here comes another big health care merger

Israel-based drug company Teva Pharmaceuticals is reportedly in talks to merge with Allergan's generic drug company, the Wall Street Journal reports. An official announcement on the deal — valued at $45 billion — could come as early as Monday, according to sources cited by The Journal. Allergan's generic drug unit would be "spun off and combined with Teva," The Journal says. Before news of the potential Teva-Allergan link-up, Teva had been unsuccessfully pursuing another merger with generic ...